- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01142518
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)
A Prospective Analysis of MS Patients After Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The treatment of relapsing-remitting MS with interferon-beta has established itself as first-choice treatment. In previous clinical studies, the interferon-beta 1a (Rebif) used within the scope of this PMS study has demonstrated significant efficacy in all aspects of treatment - magnetic resonance imaging (MRI) data, relapse rate, progression of disability of MS. The PRISMS-4 study demonstrated that treatment with Rebif reduces the frequency and severity of clinical relapses over 4 years and slows the progression of disability.
In the course of treatment escalation according to the Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) guidelines, MS subjects with correspondingly high disease activity were predominantly put on mitoxantrone. The duration of treatment is on principle limited by a cumulative lifelong total dose of 140 mg/m2 body surface area, which may not be exceeded due to the known cardiologic adverse effects. If the cumulative mitoxantrone maximum dose is reached and if the subject is in a stable condition, the question of further treatment options presents itself. One possibility is the so-called 'deescalation', that is, the return to immunomodulating baseline treatment.
Currently there is an increasing number of subjects who are in this phase of the disease and are eligible for corresponding treatment decisions.
OBJECTIVES
Primary objective:
- To systematically investigate the safety, benefit and course of Rebif (44 μg x 3 ),treatment in a larger number of subjects and to subject these data to standardized analysis
Studietyp
Inskrivning (Faktisk)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Subjects with a clinically demonstrated diagnosis of MS and present relapses
- Subjects who were relapse-free for the past 6 months with an Expanded Disability Status Scale (EDSS) range between 2 and 6
- Subjects who had a stable disease status during the past few months
- The last administration of mitoxantrone had been more than 3 months previously. In addition, the mitoxantrone treatment was given for at least a 12-month period, but for not more than 24 months, within a total dosage of 60-120 mg/m2 body surface area
Exclusion Criteria:
- Subjects with MS with secondary progression (SPMS) without relapse activity, pregnant or breast-feeding patients, as well as subjects with contraindications
- Subjects with existing systemic concomitant diseases (e.g. diabetes, heart, liver or kidney diseases)
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Stabilization of the course of the disease in MS subjects previously treated with mitoxantrone
Tidsram: 24 months
|
24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Safety and tolerance of the treatment
Tidsram: 24 months
|
Assessment of adverse events
|
24 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Sjukdomar i nervsystemet
- Immunsystemets sjukdomar
- Demyeliniserande autoimmuna sjukdomar, CNS
- Autoimmuna sjukdomar i nervsystemet
- Demyeliniserande sjukdomar
- Autoimmuna sjukdomar
- Multipel skleros
- Skleros
- Multipel skleros, skov-remitterande
- Läkemedels fysiologiska effekter
- Anti-infektionsmedel
- Antivirala medel
- Antineoplastiska medel
- Immunologiska faktorer
- Adjuvans, immunologiska
- Interferoner
- Interferon beta-1a
- Interferon-beta
Andra studie-ID-nummer
- IMP28169
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Återkommande-remitterande multipel skleros
-
Asuman KucukonerAvslutadMultipel skleros-Relapsing-RemittingKalkon
-
McGill UniversityNovartisAvslutadMultipel skleros-Relapsing-RemittingKanada
-
University Hospital MuensterOkändKliniskt isolerat syndrom, CNS demyeliniserande | Multipel skleros - Relapsing RemittingTyskland
-
Association de Recherche Bibliographique pour les...Centre Hospitalier Universitaire de Nice; Centre Hospitalier Princesse...AvslutadFriska | Kliniskt isolerat syndrom | Multipel skleros (MS) | Radiologiskt isolerat syndrom | Multipel skleros (MS) Relapsing Remitting | Multipel skleros (MS) Primär progressiv | Multipel skleros (MS) Sekundär progressivMonaco
-
Shirley Ryan AbilityLabEunice Kennedy Shriver National Institute of Child Health and Human Development... och andra samarbetspartnersHar inte rekryterat ännuMultipel skleros | Multipel skleros, sekundär progressiv | Multipel skleros-Relapsing-RemittingFörenta staterna
-
RenJi HospitalAbelZeta Pharma Inc.RekryteringSystemisk lupus erythematosus (SLE) | Neuromyelit Optica Spectrum Disorders | Immunförmedlad nekrotiserande myopati | Multipel skleros-Relapsing-RemittingKina
Kliniska prövningar på Interferon beta 1a
-
BiocadAvslutadMultipel sklerosRyska Federationen
-
Merck KGaA, Darmstadt, GermanyAvslutadÅterkommande-remitterande multipel sklerosTyskland, Estland, Lettland, Litauen, Finland, Österrike, Danmark, Nederländerna, Portugal, Schweiz, Norge, Italien
-
Centre Hospitalier Universitaire VaudoisBioPartners GmbHAvslutadMultipel skleros, skov-remitterande
-
CinnagenAvslutadÅterkommande förlöpande multipel skleros (RRMS)Iran, Islamiska republiken
-
BiogenAvslutadÅterkommande förlöpande multipel sklerosPortugal
-
EMD SeronoMerck Serono International SAAvslutadUlcerös kolitSverige, Tyskland, Nederländerna, Israel, Singapore, Schweiz, Storbritannien
-
BiogenIndragenÅterkommande multipel skleros
-
BiocadAvslutadMultipel skleros, skov-remitterandeRyska Federationen
-
BiogenAvslutadMultipel sklerosFörenta staterna